Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jordan J Feld

Showing results (271-280 of 333) with videos related to

Pageof 34
Sort By:
Open Forum Infectious Diseases|July 2, 2026
Optimizing Hepatitis C Virus Antibody Testing Strategy and Setting: Results From a Large Real-World Screening ProgramGrishma Hirode, Camelia Capraru, Aaron Vanderhoff, et al.
Gastroenterology|October 27, 2015
Effectiveness of Simeprevir Plus Sofosbuvir, With or Without Ribavirin, in Real-World Patients With HCV Genotype 1 InfectionMark S Sulkowski, Hugo E Vargas, Adrian M Di Bisceglie, et al.
Hepatology (Baltimore, Md.)|September 16, 2020
Low Incidence of Adverse Outcomes in Adults With Chronic Hepatitis B Virus Infection in the Era of Antiviral TherapyAnna S Lok, Robert Perrillo, Christina M Lalama, et al.
Gut|May 13, 2014
Reliable prediction of clinical outcome in patients with chronic HCV infection and compensated advanced hepatic fibrosis: a validated model using objective and readily available clinical parametersAdriaan J van der Meer, Bettina E Hansen, Giovanna Fattovich, et al.
Hepatology (Baltimore, Md.)|November 4, 2025
AASLD/IDSA Practice Guideline on treatment of chronic hepatitis BMarc G Ghany, Calvin Q Pan, Anna S Lok, et al.
The American Journal of Gastroenterology|September 1, 2021
High Sustained Virologic Response Rates of Glecaprevir/Pibrentasvir in Patients With Dosing Interruption or Suboptimal AdherencePhilippe J Zamor, Ashley Brown, Douglas E Dylla, et al.
Canadian Liver Journal|February 23, 2026
The 14th Canadian Symposium on Hepatitis C Virus: From research breakthroughs to equitable health care for priority populationsDaniel N Elakpa, David Lawton, Trinity H Tooley, et al.
BMJ Open Gastroenterology|April 19, 2024
Progression of the FIB-4 index among patients with chronic HCV infection and early liver diseaseLisette A P Krassenburg, Raoel Maan, Amy Puenpatom, et al.
Journal of Hepatology|May 23, 2021
Sofosbuvir/velpatasvir for 12 vs. 6 weeks for the treatment of recently acquired hepatitis C infectionGail V Matthews, Sanjay Bhagani, Marc Van der Valk, et al.
The Journal of Infectious Diseases|July 21, 2021
The Inflammatory Cytokine Profile Associated With Liver Damage Is Broader and Stronger in Patients With Chronic Hepatitis B Compared to Patients With Acute Hepatitis BAlexandra Johnson Valiente, Kin Seng Liem, Kathleen B Schwarz, et al.
Pageof 34

Showing results (271-280 of 333) with videos related to

Sort By:
Pageof 34
Open Forum Infectious Diseases|July 2, 2026
Optimizing Hepatitis C Virus Antibody Testing Strategy and Setting: Results From a Large Real-World Screening ProgramGrishma Hirode, Camelia Capraru, Aaron Vanderhoff, et al.
Gastroenterology|October 27, 2015
Effectiveness of Simeprevir Plus Sofosbuvir, With or Without Ribavirin, in Real-World Patients With HCV Genotype 1 InfectionMark S Sulkowski, Hugo E Vargas, Adrian M Di Bisceglie, et al.
Hepatology (Baltimore, Md.)|September 16, 2020
Low Incidence of Adverse Outcomes in Adults With Chronic Hepatitis B Virus Infection in the Era of Antiviral TherapyAnna S Lok, Robert Perrillo, Christina M Lalama, et al.
Gut|May 13, 2014
Reliable prediction of clinical outcome in patients with chronic HCV infection and compensated advanced hepatic fibrosis: a validated model using objective and readily available clinical parametersAdriaan J van der Meer, Bettina E Hansen, Giovanna Fattovich, et al.
Hepatology (Baltimore, Md.)|November 4, 2025
AASLD/IDSA Practice Guideline on treatment of chronic hepatitis BMarc G Ghany, Calvin Q Pan, Anna S Lok, et al.
The American Journal of Gastroenterology|September 1, 2021
High Sustained Virologic Response Rates of Glecaprevir/Pibrentasvir in Patients With Dosing Interruption or Suboptimal AdherencePhilippe J Zamor, Ashley Brown, Douglas E Dylla, et al.
Canadian Liver Journal|February 23, 2026
The 14th Canadian Symposium on Hepatitis C Virus: From research breakthroughs to equitable health care for priority populationsDaniel N Elakpa, David Lawton, Trinity H Tooley, et al.
BMJ Open Gastroenterology|April 19, 2024
Progression of the FIB-4 index among patients with chronic HCV infection and early liver diseaseLisette A P Krassenburg, Raoel Maan, Amy Puenpatom, et al.
Journal of Hepatology|May 23, 2021
Sofosbuvir/velpatasvir for 12 vs. 6 weeks for the treatment of recently acquired hepatitis C infectionGail V Matthews, Sanjay Bhagani, Marc Van der Valk, et al.
The Journal of Infectious Diseases|July 21, 2021
The Inflammatory Cytokine Profile Associated With Liver Damage Is Broader and Stronger in Patients With Chronic Hepatitis B Compared to Patients With Acute Hepatitis BAlexandra Johnson Valiente, Kin Seng Liem, Kathleen B Schwarz, et al.
Pageof 34